Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,606 matching trials from the live ClinicalTrials.gov search.
Conditions
Brain Cancer, Glioblastoma Multiforme
Interventions
Vorinostat, Erlotinib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
Interventions
TILT-123, pembrolizumab, pegylated liposomal doxorubicin
Biological · Drug
Lead sponsor
TILT Biotherapeutics Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • New York, New York
Conditions
Metastatic Colorectal Carcinoma
Interventions
PF-05212384, FOLFIRI regimen, Bevacizumab, FOLFIRI
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
35
States / cities
Fullerton, California • Irvine, California • Los Angeles, California + 15 more
Conditions
Neoplasms
Interventions
BAY1000394
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • St Louis, Missouri • Chapel Hill, North Carolina
Conditions
Cocaine Dependence, Opioid Dependency
Interventions
levetiracetam, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Hepatocellular Carcinoma
Interventions
Tocilizumab, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Pharmacokinetics of ASP9853, Non-hematologic Malignancies
Interventions
ASP9853, Docetaxel, Paclitaxel
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee
Conditions
Resistant or Refractory Solid Tumors
Interventions
CAL056 mesylate
Drug
Lead sponsor
Calgent Biotechnology Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Los Angeles, California • San Antonio, Texas
Conditions
Solid Tumor of Epithelial Origin, Gastric Cancer
Interventions
AbGn-7
Drug
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Rockledge, Pennsylvania • San Antonio, Texas
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Leukemia, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Azacitidine, Entinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Conditions
Advanced Cancer, Various, NOS
Interventions
BMS-833923, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 5 more
Completed Phase 2 Interventional Results available

AMG 386 and Abiraterone for Advanced Prostate Cancer

NCT01553188
Conditions
Prostatic Neoplasms, Prostate Cancer, Neoplasm, Prostate, Neoplasm,Prostatic
Interventions
AMG 386, Abiraterone, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
2
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Conditions
Pancreas Cancer
Interventions
10 Gy Low-KV IORT, 15 Gy Low-KV IORT, 20 GY Low-KV IORT
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Pancreatic Cancer, Renal Cell Cancer, Breast Cancer, Melanoma, Ovarian Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, Anti-hCD70 CAR transduced PBL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions
CBT, Amitriptyline
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 12 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Sarcoma, Clear Cell
Interventions
CPI-613 + Hydroxychloroquine
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
2 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Duarte, California • Kansas City, Kansas • Ann Arbor, Michigan + 5 more
Conditions
MUC17-positive Solid Tumors
Interventions
AMG 199
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Duarte, California • Orange, California • Winston-Salem, North Carolina
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Nilotinib, Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Pancreatic Cancer
Interventions
Irinotecan, Cisplatin, Olaparib (for levels 1 and 5), Olaparib (for dose level 2), Mitomycin-C
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Conditions
Myeloma
Interventions
Pomalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
San Francisco, California • Tampa, Florida • New York, New York
Conditions
Advanced Solid Malignant Tumors, Advanced Ovarian Cancer
Interventions
U3-1565
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Detroit, Michigan • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 1 more
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
STX-241
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Neoplasms
Interventions
RO6874813
Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee